Pfizer's 7.5% dividend yield, strong R&D innovation, and defensive market position make it a smart buy. Read here for an ...

In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

GlaxoSmithKline (GSK) and Pfizer filed a stipulation to dismiss with prejudice GSK’s litigation in the United States District ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...

GSK and Pfiz­er have set­tled a law­suit al­leg­ing Pfiz­er’s RSV shot Abrys­vo in­fringed GSK’s patents. A Pfiz­er ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Just hours after thousands of U.S. Food and Drug Administration employees were shown the door, Barclay Butler, the agency’s ...

Pfizer (PFE) and GSK (GSK) settle RSV vaccine patent lawsuit, dismissing the case with prejudice. REad more here.

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...